Smith & Nephew Stock - analyst consensus and Sunday background
21.06.2026 - 07:05:55 | ad-hoc-news.de
Edited by ad hoc news Background & Management Desk. Verified prior to publication on 06/21/2026, 07:05 CET. Details in the imprint.
Smith & Nephew (GB0009223206) is a UK-based medical technology group whose stock remains a core holding in many European healthcare portfolios. With no major fresh corporate headlines this weekend, the focus shifts to the current analyst consensus and the broader background of the company.
All news and key data on Smith & Nephew stock
On the ad-hoc-news topic page and the company’s own Investor Relations site, readers will find further releases, presentations and key figures on Smith & Nephew.
What recent data show
On Friday, Smith & Nephew shares last traded around 1,125 GBX in London, placing the stock slightly below its recent day high near 1,143 GBX according to a market quote overview. This keeps the valuation roughly in the mid-range of its 52-week trading corridor.
That level implies a market capitalization in the mid-single-digit billion GBP range, putting Smith & Nephew behind the very largest global medtech names but firmly in the established large-cap bracket. For many investors, this size combines balance-sheet depth with still meaningful earnings growth potential.
Analyst views and targets
The current analyst consensus on Smith & Nephew, as aggregated on major broker and data platforms, centers on a mixed but cautiously constructive stance, typically in the Hold-to-Buy range. Price targets cluster moderately above the present market price, reflecting expectations of operational improvement rather than aggressive rerating.
Several houses have highlighted execution on margin initiatives and innovation in orthopedics as key drivers for any upside to their models. Conversely, analysts remain attentive to currency effects on reported earnings and competitive pressure from larger US medtech peers.
Background on the company
Smith & Nephew traces its roots back to the 19th century in Hull and today focuses on three core segments: orthopedics, sports medicine and ENT, and advanced wound management. The group generates most of its revenue in North America and Europe, with growing exposure to emerging markets.
Management has in recent years emphasized portfolio focus and productivity gains, including targeted disposals and recurring cost programs. At the same time, research and development spending remains a central pillar, as surgeons and hospitals demand demonstrable clinical benefits and improved procedural efficiency.
Where management is steering
Strategically, Smith & Nephew aims to lift its trading profit margin back toward mid-teens levels over the medium term, supported by product mix and operational efficiency. The company also continues to prioritize cash generation to fund disciplined bolt-on acquisitions and a progressive dividend policy.
Digital tools and robotics-assisted surgery represent another important theme, as the group invests in platforms that can strengthen its position in joint replacement and sports medicine procedures over time. These investments are capital intensive but intended to defend and expand market share.
The product behind the stock
One representative product family in Smith & Nephew’s portfolio is its advanced wound management line, which includes negative pressure wound therapy systems and modern dressings for chronic and acute wounds. These solutions address aging populations, diabetes-related ulcers and post-surgical wound care worldwide.
Where the stock trades today
The shares of Smith & Nephew (GB0009223206) trade on the London Stock Exchange at about 1,125 GBX as of 06/21/2026, 04:31 BST.
Key facts on Smith & Nephew stock
- Company: Smith & Nephew plc
- ISIN: GB0009223206
- WKN: 858992
- Ticker: SN.
- Venue: London Stock Exchange
- Price (as of 06/21/2026, 04:31 BST): 1,125.00 GBX
- Market cap: around 9,000,000,000 GBP (as of 06/21/2026)
- Sector / Industry: Health Care / Medical Technology
- Index membership: FTSE 100
- Next earnings date: not officially scheduled
This article was AI-assisted and editorially reviewed. Price and company data without warranty; prices and dates may change at short notice. No investment advice, no buy or sell recommendation. Trading securities involves risk up to total loss of capital.
